As patient-derived cells present a valuable model for disease research, iPSCs were generated within a sub-study of the Parkinson's Progression Markers Initiative (PPMI). PBMCs were reprogrammed into iPSCs by Cellular Dynamics International (CDI) and deposited in the PPMI Indiana University (IU) biorepository. Gene-revertant controls with mutations edited back to WT were generated by PPMI iPSC recipients and deposited back in the biorepository for community access, as per PPMI policy. Quality control testing was performed at CDI, including karyotype analysis, identity confirmation (genotyping of 38 SNPs), pluripotency testing (gene expression of 48 mRNAs), and mycoplasma testing. Each patient who contributed PBMCs also contributed clinical, imaging, and biosample data. This document provides an overview of the PPMI iPSCs available, sorting by Parkinson's disease diagnosis and genetic status, with information on the number of lines available and availability of gene-revertant controls for lines within the PD genetic cohorts.